Key result
Carvedilol treatment significantly decreased serum levels of 8-OHdG, a marker of oxidative DNA damage, by 19% in patients with dilated cardiomyopathy.
Why the study?
Does carvedilol reduce oxidative DNA damage (8-OHdG levels) in patients with dilated cardiomyopathy?
Observational (n=76)
No
Does carvedilol reduce oxidative DNA damage (8-OHdG levels) in patients with dilated cardiomyopathy?
Effect estimate: 19% decrease
Absolute Event Rate: 5.1% vs 6.3%
p-value: p=<0.05
Oxidative DNA damage is elevated in patients with dilated cardiomyopathy, and treatment with the antioxidant beta-blocker carvedilol may reduce this damage while improving cardiac function.
Suggests carvedilol may reduce oxidative damage in DCM; hypothesis-generating and should not yet change practice.
BACKGROUND: Oxidative stress has been implicated in the pathogenesis of chronic heart failure. The present study investigated whether the levels of 8-hydroxy-2-deoxyguanosine (8-OHdG), a marker of oxidative DNA damage, were elevated in the serum and myocardium of patients with dilated cardiomyopathy (DCM), and furthermore whether carvedilol, a vasodilating beta-blocker with antioxidant activity, could reduce the levels. METHODS AND RESULTS: Serum levels of 8-OHdG were measured by enzyme immunoassay in 56 patients with DCM and in 20 control subjects. DCM patients had significantly elevated serum levels of 8-OHdG compared with control subjects. Endomyocardial biopsy samples obtained from 12 DCM patients and 5 control subjects with normal cardiac function were studied immunohistochemically for the expression of 8-OHdG. Positive 8-OHdG staining was found in the nuclei of cardiomyocytes from DCM patients but not in those from control subjects. After treatment with carvedilol, the serum levels of 8-OHdG in DCM patients significantly decreased by 19%, together with amelioration of heart failure. CONCLUSIONS: Levels of 8-OHdG are elevated in the serum and myocardium of patients with heart failure. Treatment with carvedilol might be effective for decreasing the oxidative DNA damage.
No takes yet. Share an insight, caveat, or question.
Kono et al. (2006) conducted an observational in Dilated Cardiomyopathy (n=76). Carvedilol vs. Baseline (before treatment) was evaluated on Serum 8-OHdG levels (19% decrease, p=<0.05). Carvedilol treatment significantly decreased serum levels of 8-OHdG, a marker of oxidative DNA damage, by 19% in patients with dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: